This Quiet Tech Company Is Ahead Of Microsoft, Amazon, Bernstein Says: Is It A Buy?
Database vendor Mongodb Inc (NASDAQ: MDB) has caught the attention of analysts at Bernstein who initiated coverage on the company this week.
Bristol Myers’ Opdivo Shows Improved Clinical Benefits In Bladder Cancer At Three Years
Bristol-Myers Squibb Co (NYSE:BMY) announced three-year follow-up results from the Phase 3 CheckMate -274 Phase 3 trial of Opdivo compared to placebo…
Medtronic Scores CE Mark For Extravascular Defibrillator System For Abnormal Heart Rhythms
The European authority has approved Medtronic plc’s (NYSE:MDT) Aurora EV-ICD MRI SureScan (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV MRI SureScan defibrillation…
Stryker’s Q Guidance System Scores FDA Clearance For Cranial Applications
Stryker Corporation (NYSE:SYK) announced that its Q Guidance System with Cranial Guidance Software received FDA510(k) clearance. The Q Guidance System…
Shockwave Medical Shares Gain As Q4 Earnings Surpass Wall Street Expectations
Shockwave Medical Inc (NASDAQ:SWAV) reported Q4 FY22 revenue of $144 million, an increase of 71% year-over-year, beating the consensus of…
Analysts Weigh In On Applied Materials Earnings Print: What Investors Need To Know
Semiconductor equipment provider Applied Materials, Inc (NASDAQ: AMAT) beat the Street's expectations for its fiscal first quarter.
The Santa Clara, California-based company issued upbeat guidance for the current quarter. As a result, several prominent analysts issued notes on the stock.
Pfizer, Valneva Discontinue Certain Trial Sites For Phase 3 Study Of Lyme Disease Vaccine Candidate
Pfizer Inc (NYSE:PFE) and Valneva SE (NASDAQ:VALN) announce that Pfizer, as the study sponsor, will discontinue a significant percentage of participants in the…
Merck Says Keytruda/Chemo Combo Improved Overall Survival Compared To Chemo Alone In Gastric Cancer Settings
Merck & Co Inc (NYSE:MRK) announced results from the pivotal Phase 3 KEYNOTE-859 trial of Keytruda (pembrolizumab) with fluoropyrimidine- and platinum-containing…
Pfizer Releases Interim Update On PARP Inhibitor Combo Therapy For Prostate Cancer, Secures FDA Priority Review
Pfizer Inc (NYSE:PFE) announced results from the Phase 3 TALAPRO-2 study of Talzenna (talazoparib) in combination with Xtandi (enzalutamide) in 1,106…
Analyst Views West Pharmaceutical’s Q4 Earnings Impressive Despite Headwinds
West Pharmaceutical Services Inc (NYSE:WST) reported Q4 2022 net sales of $708.7 million, down 3%, and organic net sales growth…